Anti-C3b / iC3b antibody [7C12] (ab231078)
Key features and details
- Mouse monoclonal [7C12] to C3b / iC3b
- Suitable for: WB, ELISA
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-C3b / iC3b antibody [7C12]
See all C3b / iC3b primary antibodies -
Description
Mouse monoclonal [7C12] to C3b / iC3b -
Host species
Mouse -
Tested applications
Suitable for: WB, ELISAmore details -
Species reactivity
Reacts with: Human -
Immunogen
Full length native protein (purified). This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: human serum and plasma lysates, human liver whole tissue lysate
-
General notes
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituents: PBS, 6.97% L-Arginine -
Concentration information loading...
-
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
7C12 -
Isotype
IgG1 -
Light chain type
kappa
Associated products
-
Alternative Versions
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab231078 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 1 µg/ml. Predicted molecular weight: 68 kDa.
|
|
ELISA |
Use a concentration of 10 µg/ml.
|
Notes |
---|
WB
Use a concentration of 1 µg/ml. Predicted molecular weight: 68 kDa. |
ELISA
Use a concentration of 10 µg/ml. |
Target
-
Function
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.
Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750). -
Tissue specificity
Plasma. The acylation stimulating protein (ASP) is expressed in adipocytes and released into the plasma during both the fasting and postprandial periods. -
Involvement in disease
Complement component 3 deficiency
Macular degeneration, age-related, 9
Hemolytic uremic syndrome atypical 5
Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage. -
Sequence similarities
Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain. -
Post-translational
modificationsC3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons.
Phosphorylated by FAM20C in the extracellular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 718 Human
- SwissProt: P01024 Human
- Unigene: 529053 Human
-
Alternative names
- ASP antibody
- C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
- C3 antibody
see all
Images
-
96-well microtitre plates were coated overnight at 4°C with recombinant human C3, C3b, iC3b, and Factor H proteins, in duplicate at a concentration of 1µg/mL. Plates were blocked with 1% BSA in PBS-T (0.1% Tween®) for 1 hour before incubation with a 10-step 4x serial dilution of ab231078 from 10µg/mL for 1 hour at room temperature. Antibody binding was detected with Goat Anti-Mouse IgG H&L (HRP) (ab6789) secondary antibody at a 1 in 10000 dilution for 1 hour at room temperature. Plates were incubated with TMB ELISA substrate for 7 minutes prior to being stopped with Stop solution and absorbance measured at 450nm.
-
All lanes : Anti-C3b / iC3b antibody [7C12] (ab231078) at 1 µg/ml
Lane 1 : Human Sera diluted 1/1000 at 10 µl
Lane 2 : Purified C3 Protein at 0.1 µg
Lane 3 : Purified C3b Protein at 0.1 µg
Lane 4 : Purified iC3b Protein at 0.1 µg
Performed under reducing conditions.
Predicted band size: 68 kDa
Observed band size: 110,125,43,78 kDa why is the actual band size different from the predicted?This blot was produced using a 4-12% Bis-tris under the MOPS buffer system. The gel was run at 200V for 55 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% milk before being incubated with ab231078 overnight at 4°C at 1ug/ml. Antibody binding was detected using Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) at 1/20000 dilution for 1 hour at room temperature before imaging.
-
All lanes :
Lane 1 : Human serum diluted 1/100 at 5 µl
Lane 2 : Human plasma diluted 1/100 at 5 µl
Lane 3 : Human liver whole tissue lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 68 kDa
Additional bands at: 42 kDa (possible cleavage fragment)This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 55 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 5% milk before ab231078 and ab181602 (Rabbit anti GAPDH) were incubated overnight at 4°C at a 1ug/ml concentration and 1/10000 dilution respectively. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab231078 has been referenced in 4 publications.
- Lindorfer MA et al. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115:2283-91 (2010). PubMed: 20068220
- Kennedy AD et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280-8 (2004). PubMed: 14978136
- Kennedy AD et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101:1071-9 (2003). PubMed: 12393727
- Tosic L et al. Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose. J Immunol Methods 120:241-9 (1989). PubMed: 2786912